Overview

Switching to E-cigarettes in African-American Smokers

Status:
Not yet recruiting
Trial end date:
2025-08-30
Target enrollment:
Participant gender:
Summary
The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in African American (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, partially, or not at all, and 3) examine if harm reduction can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette smoking.
Phase:
Phase 3
Details
Lead Sponsor:
University of Kansas Medical Center
Treatments:
Varenicline